American Journal of Ophthalmology
Volume 137, Issue 3 , Pages 401-406 , March 2004

Total plasma homocysteine and primary open-angle glaucoma

  • Gloria Wang, MD

      Affiliations

    • Departments of Ophthalmology (G.W., F.A.M., R.N.W.), University of California, San Diego, San Diego, California, USA
    • ,
  • Felipe A. Medeiros, MD

      Affiliations

    • Departments of Ophthalmology (G.W., F.A.M., R.N.W.), University of California, San Diego, San Diego, California, USA
    • ,
  • Bruce A. Barshop, MD

      Affiliations

    • Pediatrics (B.A.B.), University of California, San Diego, San Diego, California, USA
    • ,
  • Robert N. Weinreb, MD

      Affiliations

    • Departments of Ophthalmology (G.W., F.A.M., R.N.W.), University of California, San Diego, San Diego, California, USA
    • Corresponding Author InformationInquiries to Robert N. Weinreb, MD, Hamilton Glaucoma Center, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093-0946, USA

,Accepted 12 September 2003.

References 

  1. Hayreh SS. Blood flow in the optic nerve head and factors that may influence it. Prog Retin Eye Res. 2001;20:595–624
  2. Weinreb RN, Cioffi GA, Harris A. Optic nerve blood flow. In:  Van Buskirk EM,  Shields B editor. 100 Years of progress in glaucoma. Philadelphia: Lippincott-Raven Healthcare; 1997;p. 59–78
  3. Flammer J, Orgul S, Costa VP, et al.  The impact of ocular blood flow in glaucoma. Prog Retin Eye Res. 2002;21:359–393
  4. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med. 1997;337:230–236
  5. McCully KS. Vascular pathology of homocysteinemia (Implications for the pathogenesis of arteriosclerosis). Am J Pathol. 1969;56:111–128
  6. Perry IJ, Refsum H, Morris RW, Ebrahim SB, Ueland PM, Shaper AG. Prospective study of serum total homocysteine concentration and risk of stroke in middle-aged British men. Lancet. 1995;346:1395–1398
  7. Ueland PM, Refsum H, Brattstrom L. Plasma homocysteine and cardiovascular disease. In:  Francis RBJ editors. Atherosclerotic cardiovascular disease, hemostasis, and endothelial function. New York: Marcel Dekker; 1992;p. 183–236
  8. Clarke R, Daly L, Robinson K, et al.  Hyperhomocysteinemia (an independent risk factor for vascular disease). N Engl J Med. 1991;324:1149–1355
  9. Selhub J, Jacques PF, Bostom AG, et al.  Association between plasma homocysteine concentrations and extracranial carotid-artery stenosis. N Engl J Med. 1995;332:286–291
  10. Biousse V, Newman NJ, Sternberg P. Retinal vein occlusion and transient monocular visual loss associated with hyperhomocystinemia. Am J Ophthalmol. 1997;124:257–260
  11. Cahill M, Karabatzaki M, Meleady R, et al.  Raised plasma homocysteine as a risk factor for retinal vascular occlusive disease. Br J Ophthalmol. 2000;84:154–157
  12. Salomon O, Moisseiev J, Rosenberg N, et al.  Analysis of genetic polymorphisms related to thrombosis and other risk factors in patients with retinal vein occlusion. Blood Coagul Fibrinol. 1998;9:617–622
  13. Pianka P, Almog Y, Man O, Goldstein M, Sela BA, Loewenstein A. Hyperhomocystinemia in patients with nonarteritic anterior ischemic optic neuropathy, central retinal artery occlusion, and central retinal vein occlusion. Ophthalmology. 2000;107:1588–1592
  14. Loewenstein A, Goldstein M, Winder A, Lazar M, Eldor A. Retinal vein occlusion associated with methylenetetrahydrofolate reductase mutation. Ophthalmology. 1999;106:1817–1820
  15. Loewenstein A, Winder A, Goldstein M, Lazar M, Eldor A. Bilateral retinal vein occlusion associated with 5,10-methylenetetrahydrofolate reductase mutation. Am J Ophthalmol. 1997;124:840–841
  16. Weger M, Stanger O, Deutschmann H, et al.  The role of hyperhomocysteinemia and methylenetetrahydrofolate reductase (MTHFR) C677T mutation in patients with retinal artery occlusion. Am J Ophthalmol. 2002;134:57–61
  17. Brown BA, Marx JL, Ward TP, et al.  Homocysteine (a risk factor for retinal venous occlusive disease). Ophthalmology. 2002;109:287–290
  18. Biousse V, Kerrison JB, Newman NJ. Is non-arteritic anterior ischaemic optic neuropathy related to homocysteine?. Br J Ophthalmol. 2000;84:555
  19. Leibovitch I, Kurtz S, Shemesh G, et al.  Hyperhomocystinemia in pseudoexfoliation glaucoma. J Glaucoma. 2003;12:36–39
  20. Bleich S, Junemann A, Von Ahsen N, et al.  Homocysteine and risk of open-angle glaucoma. J Neural Transm. 2002;109:1499–1504
  21. Ducros V, Demuth K, Sauvant MP, et al.  Methods for homocysteine analysis and biological relevance of the results. J Chromatogr B Analyt Technol Biomed Life Sci. 2002;781:207–226
  22. Nexo E, Engbaek F, Ueland PM, et al.  Evaluation of novel assays in clinical chemistry (quantification of plasma total homocysteine). Clin Chem. 2000;46:1150–1156
  23. Ducros V, Candito M, Causse E, et al.  Comparison of plasma total homocysteine determinations in 9 French hospital laboratories by using 6 different methods. Ann Biol Clin (Paris). 2002;60:421–428
  24. Jacobsen DW, Gatautis VJ, Green R. Determination of plasma homocysteine by high-performance liquid chromatography with fluorescence detection. Anal Biochem. 1989;178:208–214
  25. Clarke R, Stansbie D. Assessment of homocysteine as a cardiovascular risk factor in clinical practice. Ann Clin Biochem. 2001;38:624–632
  26. Jacobsen DW, Gatautis VJ, Green R, et al.  Rapid HPLC determination of total homocysteine and other thiols in serum and plasma (sex differences and correlation with cobalamin and folate concentrations in healthy subjects). Clin Chem. 1994;40:873–881
  27. Frigge M, Hoaglin DC, Iglewicz B. Some implementations of the boxplot. The Am Statist. 1989;43:50–54
  28. Refsum H, Ueland PM, Nygard O, Vollset SE. Homocysteine and cardiovascular disease. Annu Rev Med. 1998;49:31–62
  29. Centers for Disease Control and Prevention. Assessment of laboratory tests for plasma homocysteine—selected laboratories, July–September 1998. MMWR 1999;48:1013–1015
  30. Malinow MR, Bostom AG, Krauss RM. Homocyst(e)ine, diet, and cardiovascular diseases (a statement for healthcare professionals from the Nutrition Committee, American Heart Association). Circulation. 1999;99:178–182
  31. Sutton-Tyrrell K, Bostom A, Selhub J, Zeigler-Johnson C. High homocysteine levels are independently related to isolated systolic hypertension in older adults. Circulation. 1997;96:1745–1749
  32. Stamler JS, Osborne JA, Jaraki O, et al.  Adverse vascular effects of homocysteine are modulated by endothelium-derived relaxing factor and related oxides of nitrogen. J Clin Invest. 1993;91:308–318
  33. Tsai JC, Perrella MA, Yoshizumi M, et al.  Promotion of vascular smooth muscle cell growth by homocysteine (a link to atherosclerosis). Proc Natl Acad Sci USA. 1994;91:6369–6373
  34. Tang L, Mamotte CD, Van Bockxmeer FM, Taylor RR. The effect of homocysteine on DNA synthesis in cultured human vascular smooth muscle. Atherosclerosis. 1998;136:169–173
  35. Rodgers GM, Conn MT. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood. 1990;75:895–901
  36. Rodgers GM, Kane WH. Activation of endogenous factor V by a homocysteine-induced vascular endothelial cell activator. J Clin Invest. 1986;77:1909–1916
  37. Moore P, El-sherbeny A, Roon P, Schoenlein PV, Ganapathy V, Smith SB. Apoptotic cell death in the mouse retinal ganglion cell layer is induced in vivo by the excitatory amino acid homocysteine. Exp Eye Res. 2001;73:45–57
  38. Lipton SA, Kim WK, Choi YB, et al.  Neurotoxicity associated with dual actions of homocysteine at the N-methyl-D-aspartate receptor. Proc Natl Acad Sci USA. 1997;94:5923–5928
  39. Kim WK, Pae YS. Involvement of N-methyl-d-aspartate receptor and free radical in homocysteine-mediated toxicity on rat cerebellar granule cells in culture. Neurosci Lett. 1996;216:117–120
  40. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis (a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease). JAMA. 2001;285:2481–2485
  41. Chasan-Taber L, Selhub J, Rosenberg IH, et al.  A prospective study of folate and vitamin B6 and risk of myocardial infarction in US physicians. J Am Coll Nutr. 1996;15:136–143
  42. O'Grady H, Kelly C, Bouchier-Hayes D, Leahy A. Homocysteine and occlusive arterial disease. Br J Surg. 2002;89:838–844
  43. Verhoef P, Hennekens CH, Allen RH, Stabler SP, Willett WC, Stampfer MJ. Plasma total homocysteine and risk of angina pectoris with subsequent coronary artery bypass surgery. Am J Cardiol. 1997;79:799–801
  44. Ford ES, Smith SJ, Stroup DF, Steinberg KK, Mueller PW, Thacker SB. Homocyst(e)ine and cardiovascular disease (a systematic review of the evidence with special emphasis on case-control studies and nested case-control studies). Int J Epidemiol. 2002;31:59–70

☆ InternetAdvance publication at ajo.com Sept 16, 2003

PII: S0002-9394(03)01129-2

doi: 10.1016/j.ajo.2003.09.041

American Journal of Ophthalmology
Volume 137, Issue 3 , Pages 401-406 , March 2004

Article Tools

* Image Usage & Resolution